PEOPLE & PLACES
ATLANTA, GEORGIA
National Community Oncology Dispensing Association (NCODA) 2022 Spring Session
C
linicians and leaders shared the latest advances in oncology pharmacy operations and dispensing practices at the National Community Oncology Dispensing Association (NCODA) 2022 Spring Forum. The multi-day conference delved into new opportunities to enhance the value of pharmacy services within medically integrated oncology practices. Several discussions involved leaders from Rx To Go, the in-house oral oncolytic pharmacy of FCS, that works exclusively with the statewide practice’s physicians, clinicians and patients to provide timely dispensing and convenient home delivery of medications. A keynote presentation by FCS Medical Oncologist Michel Velez, MD, was
22
FCS Magazine
entitled: Tukysa (tucatinib) A Treatment Option for Patients with HER2-positive Metastatic Breast Cancer. Serving as panelists during interactive workshops and discussions were: Ray Bailey, BPharm, RPh, FCS Senior Director of Pharmacy Services, with “NCODA’s Non-Profit Partner Update and Donor Story: Be the Match”; Chris Elder, PharmD, BCOP, FCS Clinical Oncology Pharmacist on “Putting Positive Quality Interventions into Action: Consistent Clinical Standards and NCODA Resources”; Natasha Khrystolubova, RPh, BPharm, BCOP, Director of Pharmacy Clinical Services for RX To Go Pharmacy, and Amy Terhune, CPhT, FCS Prior Authorization Supervisor on “Prior Authorizations and Multiple Appeal Process:
How to Build a Stronger Appeal”; and Kara Sammons, CPhT, FCS Associate Director of Pharmacy Services, with “NCODA’s Center of Excellence Medically Integrated Pharmacy Accreditation.” A poster entitled “Burden of Chemotherapy-Induced Myelosuppression Among Patients with Extensive-Stage Small Cell Lung Cancer: A Retrospective Study of Data from Community Oncology Practices” provided a look at real-world data for patients with extensive-stage small cell lung cancer (ES-SCLC) and the burden of chemotherapy-induced myelosuppression (CIM). FCS Medical Oncologist Lowell L. Hart, MD, FACP, FCS Director of Pharmacy Operations Kristen Boykin, PharmD, RPh/ CPh, BCOP, BCPS; FCS Senior Director of Pharmacy Services Ray Bailey, BPharm, RPh; and FCS Chief Medical Officer of Therapeutics and Analytics Lucio N. Gordan, MD were collaborators in the study which shows that CIM has a significant trilineage impact that patients experience early in therapy. These findings are contrary to the popular bias that CIM only shows up in one cell line or later in therapy.
